Bicillin-3 as means for prevention and early therapy of acute sulphur mustard injuries

FIELD: pharmacology.

SUBSTANCE: for prevention and early therapy of acute injuries with sulfur mustard, a known drug is proposed to be used, which is a penicillin preparation bicillin-3.

EFFECT: protective effectiveness in terms of resorptive action of sulfur mustard, bicillin-3 is not inferior to the prototype, but it is used at a 20 times lesser dose and 5 times smaller volume with a more optimal route of administration, which indicates its advantage when necessary for mass use for prevention and early treatment.

3 tbl, 3 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: what is presented is a method for acute exposure to organophosphates with pronounced non-anticholinesterase mode of toxicity. A method consists in preventive administration of β-oestradiol 100 mg/kg 20-60 min prior to application of the toxic agent organophosphate.

EFFECT: reducing the manifestations of first signs of the exposure, developing convulsions and complete elimination of animals' death experimentally, administering β-oestradiol 5 days or 1 day before the exposure has not been producing such an effect.

3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to mixed cobalt (II) salts of ketocarboxylic and mercaptocarboxylic acids of general formula (I):

where R=Alk, R'=H, Alk, NH2, NHCOCH3, m=0-3, R"=H, Alk, COOH, n=0-3, where Alk=alkyl C1-C3, or to such compounds as a cobalt (II) salt of mercaptoacetic acid and pyruvic acid, a cobalt (II) salt of mercaptoacetic acid and α-ketoglutaric acid, a cobalt (II) salt of N-acetyl-L-cysteine and pyruvic acid, a cobalt (II) salt of α-ketoglutaric acid and L-cysteine, a cobalt (II) salt of pyruvic acid and 2-mercaptopropionic acid or hydrates or solvates thereof. A method of producing salts of general formula (I) is also disclosed.

EFFECT: invention enables to obtain mixed cobalt (II) salts of ketocarboxylic and mercaptocarboxylic acids, having cyanide antidote activity.

7 cl, 7 ex

FIELD: medicine.

SUBSTANCE: preparation shows an antitoxic activity, and can be used as an antidote for nitrite and nitrate poisoning. A complex compound of 5-hydroxy-6-methyluracil with ascorbic acid (5-hydroxy-6-methyluracil ascorbate) is described by formula: The preparation contains the complex compound in an amount of 0.3-0.4 wt %, and ascorbic acid - the rest. The method for producing the preparation consists in a reaction of 5-hydroxy-6-methyluracil and ascorbic acid taken in the relation of ascorbic acid: 5-hydroxy-6-methyluracil equal to 1:(0.0015-0.0022), in water as a solvent at a temperature of 20-40°C for 30-60 minutes. The complex compound is produced as shown by infra-red and NMR spectra. The antitoxic activity of 5-hydroxy-6-methyluracil on nitrite has been unknown before.

EFFECT: water removal from the reaction mixture under low pressure.

2 cl, 2 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: invention is intended for treatment of acute poisoning of animals with neonicotinoid insecticides. The method comprises intravenous administration of diazepam, Ringer's solution and unitiol.

EFFECT: method improves effectively the survival of animals, reduces the concentration of neonicotinoid insecticides in the body.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology and medicine and concerns the use of dihydrobromide 9-(2-diethylaminoethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole of formula as a biologically active compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and a based pharmaceutical composition.

EFFECT: preparing the compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and the based pharmaceutical composition.

2 cl, 8 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary science. A detoxicant of polysilicic acid derivatives is specified in a group of reversed-phase sorbents.

EFFECT: using the detoxicant enables practically eliminating toxic effects accompanying animal's poisoning.

2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns veterinary science. A polyfunctional enterosorbent contains schungite-containing minerals comprising silicon dioxide 15.0-70.0 wt %, with an average median particle size 15.0*10-6 m.

EFFECT: invention provides higher efficacy on a wide spectrum of toxic substances, including mycotoxines, nitrates, nitrites, heavy metal salts, and also as an antibacterial and antioxidant agent.

14 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with carbon monoxide. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatrane) with ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of protection against poisoning by carbon monoxide by peroral introduction into organism of zinc-containing antidote in 5 vol. % ethanol in dose range 20-60 mg/kg of body weight.

EFFECT: prevention of lethal poisoning with carbon monoxide, higher efficiency and reducing acute toxicity of zinc-containing antidote.

9 cl, 5 ex.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to toxicology, and can be used for treating rats with acute verapamil intoxications. That is ensured by administering sodium thiosulphate 15-20 mg per 100 g of rat's weights as a cardioprotector.

EFFECT: method provides improved central venous pressure value.

3 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with ethanol. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatran), the ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of treating ethanol poisoning by introduction into organism of zinc-containing antidote in 5 vol.% ethanol in dose range 30-60 mg/kg of body weight.

EFFECT: prevention of lethal outcome in case of ethanol poisoning and reduction of acute toxicity of zinc-containing antidote.

9 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method of obtaining encapsulated particles of metal salts. Method of obtaining particles of metal salts encapsulated in liposoluble polymer envelope consists in the fact that metal salt, selected from the group: iron sulphate, zinc sulphate, potassium iodide or calcium chloride, is dissolved in water, obtained mixture is dispersed in sodium carboxymethylcellulose in butanol in presence of E472c and mixed, with further addition of ethanol to obtained mixture, obtained suspension is filtered and dried at room temperature, under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining microcapsules.

4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to nanotechnology, particularly a method of producing aspirin nanocapsules in a carrageenan envelope. The disclosed method includes preparing an aspirin suspension in benzene; dispersing the obtained mixture into a carrageenan suspension in butanol in the presence of an E472c preparation while mixing at 1000 rps; adding tetrachloromethane; filtering the obtained nanocapsule suspension and drying at room temperature.

EFFECT: method provides a simpler and faster process of producing nanocapsules and increases mass output.

1 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of bioencapsulation and represents method of obtaining microcapsules by method of precipitation with non-solvent, which consists in the fact that water-soluble medication of cephalosporin group, applied as core of microcapsules, and E472c as surface-active substance, are added to water solution of human leukocyte interferon in α- or β- form, applied as envelope of microcapsules, mixture is mixed, after dissolution of components carbinol is added as first precipitator, with the following addition of acetone as second precipitator, with ratio of carbinol to acetone constituting 1:5, obtained suspension of microcapsules is filtered, washed and dried at 25°C.

EFFECT: invention ensures simplification and acceleration of the process of obtaining microcapsules and reduction of loss (increase of output by weight).

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a substance-delivering carrier for the substance delivery to a bone marrow cell producing an extracellular matrix containing retinoid as a delivering agent, wherein the substance is a therapeutic agent, which inhibits the beginning, progression and/or recurrence of myelofibrosis.

EFFECT: invention provides the effective inhibition of the beginning, progression and recurrence of myelofibrosis.

10 cl, 14 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to using dermatan sulphate recovered from sulodexide for treating diseases involving metalloproteinase MMP-9: varicose veins and vascular malformations accompanied by a risk of thrombosis.

EFFECT: reducing and/or inhibiting individual's blood serum and saphena segments MMP-9 has been shown.

4 cl, 3 dwg, 13 tbl

FIELD: medicine.

SUBSTANCE: method involves administering Aevit, Unidox as a background therapy of degree I and II, and Isotretinoin and Cynovit gel as a background therapy of degree III and IV. Besides, Magnerot® 3.0 g is taken once a day (1.0 g three times a day) throughout the all background therapy.

EFFECT: invention enables providing higher clinical effectiveness in the patients with acne and connective tissue dysplasia.

1 tbl, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and describes a method for producing glucosamine sulphate nanocapsules by non-solvent addition, wherein glucosamine sulphate is added in small amounts to a carrageenan suspension used as a nanocapsule shell in butanol, containing E472c preparation 0.01 g as a surfactant; the produced mixture is agitated and added with the non-solvent hexane 6 ml, filtered, washed in hexane and dried.

EFFECT: invention provides simplifying and accelerating the process of nanoencapsulation in carrageenan and higher weight yield.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to microencapsulation, in particular, to microencapsulation of antioxidants. Carrageenan was used for the capsule shells, an antioxidant was selected from the group of: vitamins A, C, E, Q10, eleuterococcus, green tea extract, ginseng extract; wherein an antioxidant product portion was dissolved in dimethylsulfoxide, and the mixture was dispersed in a solution of carrageenan in ethanol in the presence of the preparation E472c under stirring at the rate of 1300 rev/s, the antioxidant/carrageenan weight ratio was 1:3, after which a mixture of benzene and water taken in volume ratio of 2:1 was added to the above mix, the resulted suspension was filtered and dried at a room temperature.

EFFECT: simplified and fast process of antioxidant product microencapsulation in carrageenan.

1 ex

FIELD: nanotechnology.

SUBSTANCE: suspension of aspirin in benzene is produced. The resulting mixture is dispersed into suspension of sodium alginate in butanol in the presence of the preparation E472s when stirring at 1000 rpm/sec. Then chloroform is poured, the resulting suspension of nanocapsules is filtered and dried at room temperature.

EFFECT: simplification and acceleration of the process of production of the nanocapsules, and increase in the yield by weight.

1 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to pharmaceutical composition in form of dry, free-flowing, compressible powder, which contains (a) rapamycin and mixture of (b) hydrophobic polyoxyethylene and polyoxypropylene block-copolymer and (c) hydrophilic polyoxyethylene and polyoxypropylene block-copolymer with weight proportions b:c equal from 1:3 to 1:9.

EFFECT: invention provides increase of powder compressibility and increase of rapamycin stability and bioavailability.

15 cl, 8 ex, 5 tbl

FIELD: antibiotics, pharmacy.

SUBSTANCE: invention relates to stabilization of rapamycin or rapamycin derivative with immunosuppressive properties and sensitive to oxidation. Method for stabilization involves addition of antioxidant to the purified rapamycin in small concentrations - below 1% as recalculated for rapamycin mass. Also, invention relates to a solid mixture containing rapamycin and antioxidant taken in the catalytic amount. Antioxidant represent preferably 2,6-di-tert.-butyl-4-methylphenol. The stabilized rapamycin shows high stability against oxidation, it can be stored as formulation without package before it's the following treatment and can be used in an unmodified form for preparing the required galenic composition.

EFFECT: improved stabilizing method.

14 cl, 3 dwg, 2 ex

Up!